News Research Clinical Trials

Neurosymbolic, Multiagent AI Speeds Oncology Clinical Trial Matching by Fourfold

A prospective study presents a multi-agent clinical trial matching architecture that outperforms standalone large language models and reduces screening time compared with manual review.

April 14, 2026 By Julia Cipriano, MS, CMPP 5 min read
Share

5 Key Takeaways

  • 1

    A neurosymbolic, multi-agent AI system improved oncology clinical trial matching speed by fourfold compared to manual review.

  • 2

    The AI system achieved an F1 score of 0.82, outperforming various GPT-4 baselines in trial matching tasks.

  • 3

    Median screening time decreased from 120 minutes to approximately 30 minutes with the AI system, enhancing efficiency.

  • 4

    No demographic subgroup showed an F1 gap greater than 10 percentage points, indicating algorithmic fairness in the system.

  • 5

    The study's prospective design and validation framework ensured the AI's performance reflected real clinical operations.

ASCO AI in Oncology is published by Conexiant under a license arrangement with the American Society of Clinical Oncology, Inc. (ASCO®). The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. For more information, see Policies.

KOL Commentary
Watch

Related Content